|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-4.18/-1.02
|
企业价值
23.64M
|
资产负债 |
每股账面净值
3.36
|
现金流量 |
现金流量率
--
|
损益表 |
收益
2.05M
|
每股收益
0.20
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/14 23:37 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnershipswith pharmaceutical companies, and operates in the United States. |